GSK is paying up to $750 million for global rights to a next-generation cancer immunotherapy from China’s Chimagen Biosciences — a trispecific T-cell engager (TCE) aimed at multiple myeloma. It is the latest move in GSK’s methodical rebuild of an oncology business it largely walked away from a decade ago.

What a T-cell engager does

T-cell engagers are among the hottest tools in cancer immunotherapy. The idea is elegant: a TCE is an engineered antibody that acts like a molecular matchmaker, physically grabbing a patient’s own T cells (the immune system’s killers) with one arm and latching onto a cancer cell with the other. By forcing the two into close contact, it directs the immune system to destroy the tumor. A trispecific engager goes further, binding three targets at once — typically two markers on the cancer cell plus the T cell — which can improve precision and potentially overcome the resistance that emerges when tumors lose a single target.

The deal terms

The agreement could reach $750 million in total payments — an undisclosed upfront fee plus development and commercial milestones. The program is still preclinical, with GSK planning to begin Phase 1 trials in 2027. That early stage is why the bulk of the value is tied to milestones rather than paid upfront: GSK is buying optionality on a promising molecule, not a finished product.

A pattern, not a one-off

This is GSK’s second partnership with Chimagen, following a 2024 agreement for CMG1A46, a TCE aimed at B-cell autoimmune diseases. It also fits a much larger industry trend: Western pharma companies are increasingly licensing innovative oncology assets from Chinese biotechs, which have become prolific and cost-effective sources of novel molecules.

Why GSK is doing this

There’s history here. GSK sold its cancer portfolio to Novartis in 2015, a decision that looked increasingly costly as oncology became the industry’s center of gravity. Under CEO Luke Miels, the company has been aggressively rebuilding, targeting blood cancers, women’s cancers and solid tumors using advanced modalities — TCEs, antibody-drug conjugates and tyrosine kinase inhibitors. Each deal like this one adds a shot on goal to a pipeline that had to be reconstructed almost from scratch.

The market at stake

Multiple myeloma, a cancer of plasma cells in the bone marrow, has become a proving ground for T-cell engagers. Approved drugs like Johnson & Johnson’s Tecvayli and Talvey have shown strong efficacy, and analysts project the U.S. multiple myeloma TCE market could exceed $10 billion by 2032. For GSK, even a differentiated late entrant could capture meaningful value in a market that large.

Why it matters — and the caveat

For patients, more shots on goal in multiple myeloma is welcome: despite recent advances, the disease remains incurable for most, and resistance to existing therapies is common — exactly the problem a trispecific design hopes to address. The caveat is the same as with any preclinical asset: it has years of trials ahead, and most drugs at this stage never reach market. This deal is a statement of intent and a bet on a mechanism, not a guarantee of a product. Business news, not investment or medical advice.